Rakuten TV Launches its AVOD Service in Europe
15.10.2019 11:30:00 EEST | Business Wire | Press release
Rakuten TV, one of the leading video-on-demand platforms in Europe, today announced the launch of its first AVOD - ad-supported video-on-demand - channels within the platform. This new business model will allow viewers to watch a wide range of content for free.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005048/en/
Rakuten TV's new UI 4.0 including "Free" section (Photo: Rakuten TV)
The free section of Rakuten TV will launch with an initial offer including Hollywood and local content to be expanded to additionally include exclusive Rakuten content, TV series, documentary series, news and sport channels in the coming months - with a combined linear and on-demand offer.
Among the exclusive content, Rakuten TV will present on its AVOD channel Matchday - Inside FC Barcelona, the new documentary series about FC Barcelona from the inside, offering previously unseen and exclusive scenes from the players’ private lives. Narrated by John Malkovich, Matchday – Inside FC Barcelona is a creation of Barça Studios, FC Barcelona’s own production house, in collaboration with Kosmos Studios, Rakuten, Inc. in association with Rakuten H Collective Studio and Producciones del Barrio.
Expanding its business model proposition, Rakuten TV will be the first to combine TVOD and AVOD products across Europe, meeting the changing needs of viewers. The free ad-supported channels will enrich the original proposition of Rakuten TV - Your Cinema at Home - offering Smart TV viewers the best cinematic experience with the latest new releases in the best audiovisual quality. Thanks to the presence of a remote control button providing direct access to the app on major Smart TVs, Rakuten TV content will be just a click away for over 30 million households across Europe.
In a time when the streaming industry is increasingly changing and exploring avenues such as AVOD, Rakuten TV is proud to pioneer this trend in Europe as the main VOD platform combining different business models - TVOD, AVOD and SVOD - which are oriented around meeting all audience needs.
Jacinto Roca, Rakuten TV Founder and CEO, stated: “We are incredibly proud to take this step after having tripled our presence in Europe just a few months ago. Rakuten TV continues to evolve rapidly alongside consumer trends within the industry, where there is a clear trend of advertisers moving away from linear TV and towards VOD. This is a unique opportunity for Rakuten TV which has already direct access to millions of European households through its branded remote control button of the main Smart TV brands. This is the mere beginning of a huge project which will see the launch of additional channels and exclusive content in the coming months”.
The service will be available in beta version, across the complete 2019 SMART TV line up, and will be progressively rolled out in other platforms including mobile and desktop.
Advertising sales will be managed by Rakuten Marketing, a subsidiary of Rakuten Inc. Nick Stamos, Rakuten Marketing CEO, stated: “Advertisers and agencies are eager to be among the first to showcase their brands in this exclusive and groundbreaking advertising platform. As VOD is emerging as a powerful media channel, our clients have been anticipating this launch from RakutenTV, so we are very excited to bring this new proposition to market across Europe.”
Rakuten Viber, Rakuten’s instant messaging service, will also be involved in the project, leveraging its community of 2 million Barça fans to promote Matchday.
Nielsen will be the data partner (DMP-data management platform) used to target advertisements at a digital level
This news comes alongside a renewed platform design for Rakuten TV, with a more attractive look & feel, a more intuitive user interface and a simpler user journey. Within the new interface, viewers will discover the new channel offering featuring ad-supported content inside the ‘free’ section implemented within the header menu.
The announcement took place during the conference “AVOD on the Rise” at MIPCOM 2019, where Founder and CEO of Rakuten TV, Jacinto Roca, spoke about the AVOD industry and its evolution with other top players in the entertainment field.
Rakuten TV
Rakuten TV is one of the leading Video On-Demand platforms in Europe. It offers a TVOD service (Transactional VOD) providing viewers a true cinematic experience with the latest new releases in the best audiovisual quality. It also includes an AVOD (Advertising VOD) section, Rakuten TV Free, in a blend of thematic channels embracing Hollywood classics, local, exclusive and themed content, all for free.
Rakuten TV is available in 42 countries and forms part of Rakuten, Inc., one of the world’s leading internet services companies, offering a wide variety of services for consumers and businesses, with a focus on e-commerce, fintech and digital content. Rakuten, headquartered in Japan, is also known for its partnerships with FC Barcelona, the NBA, the Golden State Warriors, Davis Cup and Spartan Race.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005048/en/
Contact information
Media Contacts:
For further information please contact:
Premier PR – Rakuten TV
Charlie Wainwright - Premier PR on behalf of Rakuten TV
charlie.wainwright@premiercomms.com
0207 292 7372
Rakuten TV
Fabiana Cumia – Communication Director – fabiana.cumia@rakuten.com
Iraia Arza – PR & Communication Specialist – iraia.arza@rakuten.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom